Balanced news tone
News Sentiment
PYPD sentiment intelligence
PolyPid news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
55
Balanced news tone
53 relevant articles
Price is moving more forcefully than the current news tone suggests.
76/100 classification confidence.
directly relevant articles
high-authority source matches
+4.2% over one week, +13.2% over four weeks, trend active, and near fair-value range.
PolyPid Ltd. (PYPD) boosts option pool by 1.5M shares and clears CEO grant
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Market update
76/100 classification
One-week reaction
4.2%
Price confirming higher
Trend fit
Trend active
13.2% over four weeks
Fair value
20.9%
Near fair-value range
Sentiment Mix
Positive, neutral, negative
Positive
13
Neutral
37
Negative
3
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Stock Titan
Direct company coverage
PolyPid Ltd. (PYPD) boosts option pool by 1.5M shares and clears CEO grant
PolyPid Ltd. (PYPD) held its Annual and Extraordinary General Meeting of Shareholders on July 15, 2026, where all four proposals were approved, including the re-election of auditors and directors, amendments to non-executive directors' option grants, and an option grant for CEO D
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jul 2026 19:40
- Source
- Stock Titan
Market source
Industry context
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 12:30
- Source
- Market source
Quartr
Direct company coverage
PolyPid (PYPD) Lytham Partners Spring 2026 Investor Conference Summary
PolyPid (PYPD) presented at the Lytham Partners Spring 2026 Investor Conference, highlighting key milestones for D-PLEX100. These include the recent NDA submission, anticipated FDA acceptance, and plans for EU MAA submission in 2027. The company also emphasized the strong clinica
- Tone
- Positive 91/100
- Event
- Market update
- Published
- 09 Jul 2026 16:40
- Source
- Quartr
Quartr
Direct company coverage
PolyPid (PYPD) The Citizens Life Sciences Conference 2026 Summary
PolyPid (PYPD) provided an update on its D-PLEX₁₀₀ drug at The Citizens Life Sciences Conference 2026, highlighting the imminent NDA submission and Breakthrough Therapy Designation. The drug demonstrated significant reduction in surgical site infections in Phase 3 trials and aims
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jul 2026 16:40
- Source
- Quartr
TradingView
Direct company coverage
Price to earnings forward of PolyPid Ltd. – NASDAQ:PYPD
This article displays the "Price to earnings forward" metric for PolyPid Ltd. under the NASDAQ:PYPD ticker. It presents a simple table showing the period, value, change, and change percentage, although no actual data is provided in the content. The page also includes standard mar
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 04 Jul 2026 08:10
- Source
- TradingView
Ad-hoc-news.de
Direct company coverage
PolyPid Ltd stock and its pipeline. A closer look at the drug-delivery specialist
PolyPid Ltd is a clinical-stage biopharmaceutical company specializing in localized, extended-release drug-delivery solutions for surgical patients, aiming to reduce systemic exposure while maintaining effective local drug concentrations. The company's stock reflects investor int
- Tone
- Positive 65/100
- Event
- Market update
- Published
- 03 Jul 2026 19:41
- Source
- Ad-hoc-news.de
Finviz
Direct company coverage
PYPD - Polypid Ltd Latest SEC Filings
This article provides the latest SEC filings and comprehensive financial data for Polypid Ltd (PYPD). It details the company's stock performance, key financial metrics such as market cap, income, sales, and employee count, as well as various valuation ratios, efficiency ratios, a
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jul 2026 06:39
- Source
- Finviz
TradingView
Direct company coverage
Price to book forward of PolyPid Ltd. – NASDAQ:PYPD
This article provides the "Price to book forward" financial metric for PolyPid Ltd. (NASDAQ: PYPD). The data is presented simply as "Period", "Value", "Change", and "Change %". No specific values for these metrics are displayed in the provided content.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jul 2026 05:39
- Source
- TradingView
TradingView
Direct company coverage
Enterprise value to EBITDA forward of PolyPid Ltd. – NASDAQ:PYPD
This article provides financial context on PolyPid Ltd. (NASDAQ: PYPD), specifically focusing on its enterprise value to EBITDA forward metric. It appears to be an excerpt from a financial data platform, likely TradingView, presenting a snapshot of the metric's period, value, and
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jul 2026 03:09
- Source
- TradingView
TradingView
Direct company coverage
PolyPid Ltd. Actuals & Estimates (NASDAQ:PYPD)
This article provides an overview of PolyPid Ltd. (NASDAQ:PYPD) stock performance, financial actuals, and analyst estimates. It includes current stock price, historical highs and lows, volatility, market capitalization, upcoming earnings dates, and past financial results like rev
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 27 Jun 2026 02:40
- Source
- TradingView
TradingView
Direct company coverage
2PV Forecast — Price Target — Prediction for 2027
This article provides a forecast for PolyPid Ltd. (2PV) stock, based on analyst opinions. It details the company's price target, historical stock performance including all-time high and low prices, earnings reports, revenue, net income, and employee count. Additionally, it confir
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 26 Jun 2026 09:12
- Source
- TradingView
TradingKey
Direct company coverage
PolyPid Ltd (PYPD) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of PolyPid Ltd (PYPD), including its support and resistance levels, various technical indicators, and moving averages. According to the analysis, the overall signal based on moving averages and other technical indicators is "Sell," with
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 25 Jun 2026 14:12
- Source
- TradingKey
TradingKey
Direct company coverage
PolyPid Ltd (PYPD) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides a historical overview of PolyPid Ltd (PYPD) dividend payouts and stock split events. It indicates that PolyPid Ltd has not distributed any dividends over the past five years. The only major stock split event listed is a 30-to-1 merger that occurred on August
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 19 Jun 2026 13:11
- Source
- TradingKey
TradingKey
Direct company coverage
PolyPid Ltd (PYPD) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of PolyPid Ltd (PYPD), listing its major shareholders and institutional holdings. Key shareholders include Aurum Ventures M.K.I., Rodney Hodges, and Centaurus Investments Limited, among others. The report also breaks down shareholder
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 22:39
- Source
- TradingKey
TradingKey
Direct company coverage
PolyPid Ltd (PYPD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article from TradingKey provides a revenue breakdown for PolyPid Ltd (PYPD), detailing its business segments, regional revenue, and profit contribution. The report indicates that relevant data for these categories have not yet been disclosed by the company. The article also
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 18 Jun 2026 21:10
- Source
- TradingKey
TradingKey
Direct company coverage
PolyPid Ltd (PYPD) Earnings Forecast: Future EPS & Revenue Growth Estimates
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 18 Jun 2026 09:23
- Source
- TradingKey
TradingKey
Direct company coverage
PolyPid Ltd (PYPD) Financial Health: Profitability & Balance Sheet Analysis
This article provides an analysis of PolyPid Ltd's (PYPD) financial health, focusing on its profitability and balance sheet. It highlights that relevant financial data regarding cash and cash equivalents, total assets, liabilities, free cash flow, revenue, operating profit, and o
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 18 Jun 2026 10:17
- Source
- TradingKey
TradingKey
Direct company coverage
PolyPid Ltd (PYPD) Institutional Confidence
This article from TradingKey provides an overview of PolyPid Ltd's (PYPD) institutional confidence, focusing on changes in shareholdings by various institutional investors. Key data points displayed include the number of shares held and the percentage change for each listed insti
- Tone
- Positive 71/100
- Event
- Market update
- Published
- 18 Jun 2026 10:10
- Source
- TradingKey
TradingKey
Direct company coverage
PolyPid Ltd (PYPD) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for PolyPid Ltd (PYPD), focusing on its volatility, financial metrics, and investment risk. It details various risk indicators such as Beta, VaR, Maximum Drawdown, Volatility, and Sharpe Ratio over different time frames, offering investors
- Tone
- Negative 30/100
- Event
- Market update
- Published
- 18 Jun 2026 09:17
- Source
- TradingKey
AD HOC NEWS
Direct company coverage
PolyPid Ltd Stock (US70450B1035): modest move as market awaits next catalyst
PolyPid Ltd (PYPD) stock experienced minimal price changes recently, closing at $4.67 after a slight gain of 0.97%. The clinical-stage biopharmaceutical company remains a speculative micro-cap, with investors anticipating future clinical, regulatory, or financing updates as major
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 16 Jun 2026 22:10
- Source
- AD HOC NEWS
StocksToTrade
Direct company coverage
PolyPid Ltd. (PYPD) Stock Price | Live Quotes & Charts | NASDAQ
This page provides live quotes and charts for PolyPid Ltd. (PYPD) stock. It shows the current stock price, recent price change, and links to real-time quotes. The article mentions that there is no current analyst rating or earnings information for PolyPid Ltd.
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 16 Jun 2026 11:39
- Source
- StocksToTrade
Intellectia AI
Direct company coverage
PYPD Technical Analysis & Stock Price Forecast
This article provides a technical analysis and stock price forecast for PolyPid Ltd (PYPD), indicating an overall "Strong Buy" consensus based on various technical indicators and moving averages. It details momentum indicators like RSI and MACD, as well as crucial support and res
- Tone
- Positive 75/100
- Event
- Guidance
- Published
- 11 Jun 2026 20:39
- Source
- Intellectia AI
Investing.com Nigeria
Direct company coverage
PolyPid schedules annual and extraordinary shareholder meeting for July 15 By Investing.com
PolyPid Ltd. (NASDAQ:PYPD) announced it will hold its Annual and Extraordinary General Meeting of Shareholders on July 15, 2026, at its headquarters in Petach Tikva, Israel. Shareholders of record as of June 15, 2026, will be eligible to vote. The meeting details, including the a
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jun 2026 21:12
- Source
- Investing.com Nigeria
Investing.com
Direct company coverage
PolyPid schedules annual and extraordinary shareholder meeting for July 15
PolyPid Ltd. (NASDAQ:PYPD) has announced that it will hold its Annual and Extraordinary General Meeting of Shareholders on July 15, 2026, at its headquarters in Petach Tikva, Israel. Shareholders of record by June 15, 2026, will be eligible to receive notice and vote at the meeti
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jun 2026 20:39
- Source
- Investing.com
Stock Titan
Direct company coverage
[6-K] PolyPid Ltd. Current Report (Foreign Issuer) | PYPD SEC Filing - Form 6-K
PolyPid Ltd. has scheduled an annual and extraordinary general meeting for shareholders on July 15, 2026, in Petach Tikva, Israel. The meeting will address proposals to re-elect independent auditors Kost Forer Gabbay & Kasierer (EY), re-elect eight directors and approve their com
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jun 2026 20:10
- Source
- Stock Titan
Simply Wall Street
Direct company coverage
When Can We Expect A Profit From PolyPid Ltd. (NASDAQ:PYPD)?
PolyPid Ltd. (NASDAQ:PYPD), a biopharmaceutical company with an US$86m market cap, is projected by analysts to achieve profitability around 2028. The company reported a US$34m loss in its last financial year but is expected to break even in approximately two years, requiring an a
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 08 Jun 2026 10:09
- Source
- Simply Wall Street
DonanımHaber
Direct company coverage
PolyPid Ltd. (PYPD) Shares Slide 6.8% as Stock Approaches Key Support at $4.27 - Market Cap Weight
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 Jun 2026 07:00
- Source
- DonanımHaber
marketscreener.com
Direct company coverage
PolyPid Completes Rolling NDA Submission to FDA for D-PLEX100
PolyPid Ltd. has finished its rolling New Drug Application (NDA) submission to the FDA for D-PLEX100, a drug designed to improve surgical outcomes by providing controlled, continuous delivery of medicines. The company, a clinical-stage biopharmaceutical firm based in Israel, conc
- Tone
- Positive 72/100
- Event
- Market update
- Published
- 01 Jun 2026 17:09
- Source
- marketscreener.com
Market source
Direct company coverage
PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀
PolyPid Ltd. has completed its New Drug Application (NDA) submission to the FDA for D-PLEX₁₀₀, a drug designed to prevent surgical site infections during colorectal surgery. The submission is supported by positive Phase 3 trial results showing a 60% relative risk reduction in inf
- Tone
- Positive 70/100
- Event
- Earnings
- Published
- 01 Jun 2026 17:09
- Source
- Market source
Investing.com
Direct company coverage
PolyPid completes NDA submission for surgical infection drug
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jun 2026 07:00
- Source
- Investing.com